Dec 20, 2024 · Grifols is a leading global healthcare company. Our trusted and innovative plasma-derived medicines, other biopharmaceuticals and solutions in transfusion medicine enable millions of patients around the world to lead more productive lives.

products & services This information is aimed exclusively at authorized healthcare professionals to prescribe or supply medicinal products and its correct interpretation requires specialized training.

An experienced and trusted partner to blood banks and hospital transfusion centers, Grifols is a global leader in transfusion medicine and a pioneer in disease detection. Learn how our diagnostic solutions can help improve and simplify your laboratory operations.

Grifols is increasingly diversifying its therapeutic approach with a portfolio of innovative non-plasma treatments such as a new class of recombinant protein candidates and small-molecule pharmaceuticals.

Grifols USA was established in 2003. Based in Los Angeles, we cover the U.S. market where we offer a comprehensive portfolio of Grifols products and services. The company is one of the largest producers of life-saving plasma medicines and other innovative biopharmaceutical solutions in the world.

As Grifols grew into a global plasma leader over the last 50 years, the company became increasingly known for its industrial excellence, with advanced machinery, robotics and equipment for highly sophisticated and efficient manufacturing operations.

We are advancing additional intravenous Ig products, manufactured using an innovative production process, for the treatment of primary immunodeficiencies and autoimmune diseases such as chronic immune thrombocytopenia (ITP), for which Grifols also provides a …

Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.

Understanding the mechanisms of action through which our therapies impact human health has already enabled Grifols to help enhance the daily lives of millions of patients and their families.

Nov 13, 2023 · New building increases Grifols’ global capacity to produce its leading Gamunex ®-C immunoglobulin (Ig) brand to 60 million grams annually; next up for FDA review is the plant’s output of XEMBIFY ®, the company’s subcutaneous Ig